Life-Itra 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible organisms, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased membrane permeability and ultimately fungal cell death. Life-Itra 200 Capsule is administered orally and is well absorbed when taken with food, enhancing its bioavailability. The dosage and duration of therapy depend on the type and severity of the infection, as well as patient-specific factors such as age and hepatic function. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and elevated liver enzymes; therefore, liver function tests should be monitored during prolonged therapy. Caution is advised in patients with hepatic impairment or congestive heart failure. Life-Itra 200 Capsule may interact with several drugs metabolized via the cytochrome P450 system, necessitating careful review of concomitant medications. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals. Proper adherence to prescribed dosing ensures optimal therapeutic outcomes in managing fungal infections.